METiS, a US-China AI Company, Raises $86 Million in Series A

METiS Therapeutics of Cambridge, MA raised $86 million in a Series A Round to develop its artificial intelligence (AI) and machine learning platform for drug discovery and formulation/delivery. The company will use the proceeds for its pipeline of novel assets, a pipeline the company believes has high potential therapeutic value. The funding included only China investors, and METiS has operations in China . The A round was led by Beijing 's PICC PE and China Life. It included Sequoia Capital China, Lightspeed, 5Y Capital, FreeS Fund and CMBI Zhaoxin Wuji Fund. More details.... Share this with colleagues: // //